SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging in conversation as a self-described Bitcoin parody that leans into its origins as an early 2011 internet joke to differentiate itself from newer meme coins. The community is actively debating its potential as a 'next-gen' asset, highlighting its long-standing lore and historical ties to the broader crypto ecosystem while dismissing recent unrelated copycats as scams.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is currently generating significant market conversation following a Canary Capital ETF filing that has renewed institutional interest and fueled community speculation about a potential major upward move. Investors are actively debating the token's long-term meme status versus its utility as a blue-chip asset, with many focusing on its price action as a key indicator of broader altcoin market health and potential rotation from Bitcoin.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is capturing market attention as the bank navigates a complex environment of shifting private credit regulations and internal loan markdowns, while analysts closely monitor its role in major upcoming IPOs and the broader impact of AI-driven cyber threats on the financial sector. The community is actively debating the bank's defensive positioning and potential earnings strength, with traders specifically focused on its institutional options activity and price action relative to key sector support levels.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is currently a focal point for investors as they anticipate a transformative FDA Biologics License Application (BLA) decision for their lead drug candidate, ivonescimab, which is being positioned as a potential disruptor in the lung cancer treatment landscape. The community is intensely focused on the company's clinical pipeline, with active discussions centering on the upcoming interim progression-free survival data and the broader competitive threat the drug poses to existing blockbuster immunotherapies.

Citigroup Global Markets Holdings, Inc. provides investment banking and securities brokerage services. It offers financial advisory, research and capital raising services to corporations, governments and individuals. The company was founded in 1977 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is currently drawing significant attention from investors as it hits fresh 52-week highs, driven by a combination of successful strategic divestitures in markets like Russia and Mexico and growing market optimism surrounding its long-term profitability overhaul. Traders are actively debating the sustainability of this recent rally, closely monitoring upcoming earnings as a potential catalyst while reacting to regulatory developments that are viewed as a positive signal for the bank's operational flexibility.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is trending as investors weigh its role as a lead underwriter for the massive anticipated SpaceX IPO and monitor the bank's active positioning in hedging private credit risk through new credit default swap indices. Additionally, market sentiment is being driven by the firm's robust performance metrics heading into the earnings cycle and its strategic expansion into AI-related infrastructure financing.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is currently a focal point of intense community debate, with holders balancing optimistic speculation regarding potential supply burns and institutional status against widespread skepticism about its long-term performance. While some participants view current price levels as a strategic accumulation zone, others remain vocal about the asset's volatility and its historical correlation with broader market downturns.

Hormel Foods Corp. engages in the manufacturing and marketing of branded food products. It operates through the following segments: Retail, Foodservice, and International. The Retail segment consists of the processing, marketing, and sale of food products sold predominantly in the retail market. The Foodservice segment includes the processing, marketing, and sale of food and nutritional products for foodservice, convenience store, and commercial customers. The International segment focuses on processing, marketing, and selling company products internationally. The company was founded by George A. Hormel in 1891 and is headquartered in Austin, MN.

Hormel Foods Corp.

Hormel Foods is facing increased volatility and investor scrutiny following a recent rating downgrade from JPMorgan, which cited mounting cost pressures and reduced growth expectations. The community remains deeply divided, with some investors leveraging the depressed valuation to collect dividends, while others express frustration over stagnant performance and the need for structural cost-cutting.

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.

Aktis Oncology Inc

Akoustis Technologies Inc

Akoustis Technologies has completed the sale of its assets to a subsidiary of SpaceX, formally concluding its Chapter 11 bankruptcy process. The community is actively discussing the impact of this liquidation, with many shareholders expressing that their equity positions have been wiped out following the finalization of the sale.

ConocoPhillips is an exploration and production company, which engages in the exploration, production, transport, and marketing of crude oil, bitumen, and natural gas. It operates through the following geographical segments: Alaska, Lower 48, Canada, Europe, Middle East, and North Africa, Asia Pacific, and Other International. The Alaska segment explores for, produces, transports and markets crude oil, natural gas and NGLs. The Lower 48 segment consists of operations located in the 48 contiguous U.S. states and the Gulf of Mexico. The Canada segment refers to oil sands development in the Athabasca Region of northeastern Alberta and a liquids-rich unconventional play in western Canada. The Europe, Middle East, and North Africa segment includes operations in the Norwegian sector of the North Sea, the Norwegian Sea, Qatar, Libya, Equatorial Guinea and commercial and terminalling operations in the U.K. The Asia Pacific segment focuses on explorations and product operations in China, Indonesia, Malaysia, and Australia. The Other International segment handles exploration activities in Columbia and Argentina. The company was founded by Isaac Elder Blake on November 25, 1875 and is headquartered in Houston, TX.

Conoco Phillips

ConocoPhillips is currently trending as investors weigh strong production performance and ongoing cost-synergy gains from the Marathon Oil acquisition against broader industry concerns over softening oil prices. The community is actively discussing the stock's resilience and dividend sustainability while monitoring how geopolitical tensions might influence future energy supply dynamics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jeff Knight Sells 85,163 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Jeff Knight sold 85,163 shares of the company's stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $40.10, for a total transaction of $3,415,036.30. Following the completion of the sale...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Jeff Knight Sells 85,163 Shares

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Jeff Knight sold 85,163 shares of the business's stock in a transaction that occurred on Wednesday, April 8th. The stock was...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on March 3rd...

Aberdeen Group plc Buys 334,584 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Aberdeen Group plc lifted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 98.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the stock, MarketBeat...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen lowered Crinetics Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More

Key PointsA director of Crinetics Pharmaceuticals reported that he sold 5,000 shares of the company for a transaction value of approximately $180,761 on March 12, 2026...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.3% - Here's Why

Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Down 4.3% - Time to Sell...

JPMorgan Chase & Co. Acquires 926,765 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

JPMorgan Chase & Co. lifted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 279.2% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 1,258,722 shares of the company's stock after acquiring an additional 926,765 share...

Richard Scott Struthers Sells 21,981 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) CEO Richard Scott Struthers sold 21,981 shares of the firm's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $37.37, for a total value of $821,429.97. Following the transaction, the chief...

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

CRNX
Crinetics Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CRNX News

CRNXCrinetics Pharmaceuticals Inc